Business Daily from THE HINDU group of publications
Tuesday, Jul 29, 2008
ePaper | Mobile/PDA Version | Audio
Business Daily from THE HINDU group of publications Tuesday, Jul 29, 2008 ePaper | Mobile/PDA Version | Audio |
|
|
|
|
|
Corporate
-
Alliances & Joint Ventures Web Extras - Pharmaceuticals
Our Bureau New Delhi, July 28 Ranbaxy Pharmaceuticals Inc (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Ltd (RLL), announced on Monday that it has entered into an agreement with AstraZeneca Pharmaceuticals to launch an authorised generic of Omeprazole 40 mg capsules in the US. The drug is indicated for the treatment of acid-related disease, including gastric ulcer. It had sales in the US market of $204.2 million.
“We welcome the opportunity to market an authorised generic of Omeprazole 40 mg capsules that will be commercialised immediately to all classes of trade in the US healthcare system under the Ranbaxy label. “We will offer this product as an affordable and accessible generic formulation to patients requiring this medication,” said Mr Jim Meehan, Vice-President of Sales and Distribution for RPI. Ranbaxy launches hypertension drug in Japan Generic drug makers’ concern over Ranbaxy-USFDA stand-off Ranbaxy gets tentative USFDA nod for AIDS drug More Stories on : Alliances & Joint Ventures | Pharmaceuticals | Ranbaxy Laboratories Ltd
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
 |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2008, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|